Spontaneous Resolution of Vitreomacular Traction following Ranibizumab (Lucentis) Injection

2008 ◽  
Vol 18 (2) ◽  
pp. 301-303 ◽  
Author(s):  
A. Rouvas ◽  
P. Petrou ◽  
I. Ladas ◽  
G. Neamonitou ◽  
I. Vergados
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Retinal Thickness ◽  
Spontaneous Resolution ◽  
Vitreomacular Traction ◽  
Diabetic Patients ◽  
Vascular Endothelial ◽  
Case Presentation ◽  
Vitreomacular Traction Syndrome ◽  
Endothelial Growth Factor

Purpose Spontaneous resolution of vitreomacular traction syndrome in diabetic patients is a rare phenomenon that has been poorly described in the literature. Methods Case presentation. Results The authors present a case of spontaneous resolution of vitreomacular traction following intravitreal administration of ranibizumab. Conclusions In patients with vitreomacular traction syndrome and diabetic macular edema, the combination of the possible vitreous liquefaction and mechanical increase of vitreous volume caused by an intravitreal injection with a degree of reduction in retinal thickness caused by the effect of vascular endothelial growth factor inhibition could play a role in the resolution of vitreomacular traction.

scholarly journals The Role of Focal Laser in the Anti–Vascular Endothelial Growth Factor Era

2017 ◽  
Vol 9 ◽  
pp. 117917211773824 ◽  
Author(s):  
Jason N Crosson ◽  
Lauren Mason ◽  
John O Mason
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Visual Acuity ◽  
Growth Factor ◽  
Macular Edema ◽  
Real World ◽  
Pharmacologic Therapy ◽  
Diabetic Patients ◽  
Vascular Endothelial ◽  
Real World Data ◽  
Endothelial Growth Factor

Introduction: To review important studies examining focal laser for diabetic macular edema (DME), to examine real-world data regarding actual treatments patients are receiving, to present long-term visual outcomes in real-world practice, and to suggest an evidence-based approach for the use of focal laser. Methods: This study is a review of landmark studies evaluating focal laser and pharmacologic therapy for DME. In addition, the authors include a retrospective review of 102 consecutive eyes of 53 patients in our practice setting in rural Alabama. A chart review was performed, and patients were included if they were diagnosed with DME and were treated with both focal laser and bevacizumab. Bevacizumab and focal laser were given on a “as needed basis” at the discretion of one treating physician (J.O.M.). Worse visual acuity or worsening macular edema were indications for additional treatment. Statistical analysis was performed using frequencies and percentages. Best-corrected visual acuity (BCVA) was recorded at baseline and at the end of treatment (mean of 5 years) in the medical record. Primary outcome measures were BCVA, patients with better than 20/40 BCVA, patients with worse than 20/200 BCVA, and patients with stable BCVA. Results: Anti–vascular endothelial growth factor (VEGF) therapies are the first-line treatment for DME, but real-world claims data suggest that diabetic patients cannot come in for monthly injections as in large clinical trials. In our series, after a mean of 5 lasers and 5.5 injections, 90% of eyes had stable or better BCVA, 65% were ≥20/40, and only 13% were ≤20/200. Conclusions: Laser treatment for DME remains an important adjunctive therapy

Sign in / Sign up

Export Citation Format

Share Document